A Paradigm for Targeting Functional Impairment as an Outcome in Attention-Deficit/Hyperactivity Disorder
- PMID: 36009077
- PMCID: PMC9405930
- DOI: 10.3390/brainsci12081014
A Paradigm for Targeting Functional Impairment as an Outcome in Attention-Deficit/Hyperactivity Disorder
Abstract
Although functional impairment is required for a diagnosis in the DSM 5, the time frame and definition of functional impairment is ambiguous. We present a conceptual review clarifying the difference between functional impairment as a stable trait representing strength or disability in various domains, and functional impairment as secondary to emotional or behavior problems, which is a state sensitive to change with treatment intervention. Functional impairment as a measure of treatment outcome includes both change from baseline and status at the endpoint of treatment. When using a validated measure of function, functional improvement can be defined as the percentage of patients who achieve the Minimal Important Clinical Difference (MCID) and functional remission as the percentage of patients who normalize at treatment endpoint. True treatment remission should be defined as both symptomatic and functional remission.
Keywords: ADHD; attention deficits; endpoint treatment; functional impairment; hyperactivity; measurement; outcome; rating scales; remission.
Conflict of interest statement
The author declares a conflict of interest in discussing measurement of functional impairment, in that she is the author of the WFIRS scale described in that section and receives royalties from Multi-Health Systems. Weiss has received consultant fees from Adlon, CBPartners, Tris, and Putnam Associates. She has been on the Advisory board of Idorsia and Revibe.
Similar articles
-
Relationship Between Symptomatic and Functional Improvement and Remission in a Treatment Response to Stimulant Trial.J Child Adolesc Psychopharmacol. 2018 Oct;28(8):521-529. doi: 10.1089/cap.2017.0166. Epub 2018 Jul 23. J Child Adolesc Psychopharmacol. 2018. PMID: 30036076 Free PMC article.
-
Health-related quality of life and functional outcomes from a randomized-withdrawal study of long-term lisdexamfetamine dimesylate treatment in children and adolescents with attention-deficit/hyperactivity disorder.CNS Drugs. 2014 Dec;28(12):1191-203. doi: 10.1007/s40263-014-0193-z. CNS Drugs. 2014. PMID: 25139785 Free PMC article. Clinical Trial.
-
A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Viloxazine Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity Disorder.CNS Drugs. 2022 Aug;36(8):897-915. doi: 10.1007/s40263-022-00938-w. Epub 2022 Jul 27. CNS Drugs. 2022. PMID: 35896943 Free PMC article. Clinical Trial.
-
Psychopathological rating scales for diagnostic use in adults with attention-deficit/hyperactivity disorder (ADHD).Eur Arch Psychiatry Clin Neurosci. 2006 Sep;256 Suppl 1:i3-11. doi: 10.1007/s00406-006-1001-7. Eur Arch Psychiatry Clin Neurosci. 2006. PMID: 16977549 Review.
-
Achieving remission as a routine goal of pharmacotherapy in attention-deficit hyperactivity disorder.CNS Drugs. 2011 Jan;25(1):17-36. doi: 10.2165/11538450-000000000-00000. CNS Drugs. 2011. PMID: 21128692 Review.
Cited by
-
How Do Personality Dysfunction and Maladaptive Personality Traits Predict Time to Premature Discontinuation of Pharmacological Treatment of ADHD?J Atten Disord. 2025 Mar;29(5):351-362. doi: 10.1177/10870547241309524. Epub 2025 Jan 23. J Atten Disord. 2025. PMID: 39846354 Free PMC article.
-
Testing the Use of "Clinical Checks" With the International Trauma Questionnaire to Measure PTSD and Complex PTSD.Acta Psychiatr Scand. 2025 Jul;152(1):49-59. doi: 10.1111/acps.13799. Epub 2025 Mar 23. Acta Psychiatr Scand. 2025. PMID: 40122678 Free PMC article.
-
Real-World Efficacy and Safety of Extended-Release Methylphenidate (PRC-063) in the Treatment of ADHD in Pediatric and Adult Subjects: Results of a Phase IV Multicenter Comparison With Lisdexamfetamine Dimesylate.J Atten Disord. 2023 May;27(7):743-756. doi: 10.1177/10870547231172767. Epub 2023 May 5. J Atten Disord. 2023. PMID: 37144295 Free PMC article.
-
Impairment Assessment in Adult ADHD and Related Disorders: Current Opinions From Clinic and Research.J Atten Disord. 2024 Oct;28(12):1529-1541. doi: 10.1177/10870547241261598. Epub 2024 Jun 19. J Atten Disord. 2024. PMID: 38898706 Free PMC article.
-
Measuring clinical outcomes in adult ADHD clinics: psychometrics of a new scale, the adult ADHD Clinical Outcome Scale.BJPsych Open. 2024 Oct 14;10(6):e180. doi: 10.1192/bjo.2024.739. BJPsych Open. 2024. PMID: 39397668 Free PMC article.
References
-
- Barkley R.A., Cunningham C.E., Gordon M., Faraone S.V., Lewandowski L., Murphy K.R. ADHD Symptoms vs. Impairment: Revisited. ADHD Rep. 2006;14:1–9. doi: 10.1521/adhd.2006.14.2.1. - DOI
Grants and funding
LinkOut - more resources
Full Text Sources